Clinical Trial Update: Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) [Phase 1]

View source ↗

Summary

Phase 1 trial update on VIRAGE, rapidly generated multivirus-specific cytotoxic T-lymphocytes, for viral infections in the context of stem cell transplantation.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenovirus Infection
• Cytomegalovirus Infection
• Epstein-barr Virus Infection

Drugs mentioned

• VIRAGE (multivirus-specific cytotoxic T-lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Adenovirus Infection, Epstein-Barr Virus Infections | Phase 1 | Status: COMPLETED